Clinical Trial

Phase I Study of Preconditioning Radiation Therapy With IL-15 Transduced TGFBR2 KO CAR.TROP2-engineered Cord Blood-derived NK Cells in Patients With Advanced Head and Neck Cancer (RADIANCE-NK)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
To find the recommended dose of an investigational therapy called chimeric antigen receptor (CAR).TROP2/interleukin (IL)15-transduced TGFBR2 KO cord blood (CB)-derived natural killer (NK) cells (TROP2 CAR/IL-15 TGFBR2 KO NK cells) that can be given with and without preconditioning radiation therapy in patients with advanced head and neck squamous cell carcinoma.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2025-07-28; most recent amendment 2026-07-20.
Status change: Active, Not Recruiting → Recruiting 2026-01-01
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-11-13
Trial Details
NCT Number NCT07101432
Lead Sponsor M.D. Anderson Cancer Center
Conditions Head and Neck Cancer
Enrollment 33 participants
Start Date 2025-12-19
Primary Completion 2027-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-22